Core Viewpoint - The company, Aihuilong (688575.SH), announced that its controlling shareholder and chairman, Hu Kunhui, reduced his shareholding through a block trade, impacting the overall ownership structure of the company [1] Group 1 - Hu Kunhui reduced his shareholding by selling a total of 600,000 shares on November 17-18, 2025 [1] - After the reduction, Hu Kunhui and his concerted parties hold a total of 267,851,515 shares, decreasing their combined ownership percentage from 47.06% to 46.96% [1] - The change in equity ownership triggered a 1% integer change in the shareholding structure [1]

Core Insights - Shenzhen Yahui Long Biotechnology Co., Ltd. has received approval for its self-developed soluble CD146 detection kit (chemiluminescence method) from the Guangdong Provincial Drug Administration, marking a significant breakthrough in the detection of central nervous system diseases [1][2] - The company is the first globally to offer a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Product Development and Innovation - The soluble CD146 detection kit demonstrates a notable increase in sCD146 concentration in cerebrospinal fluid among patients with multiple sclerosis (MS) and neuromyelitis optica, addressing the challenge of early and accurate diagnosis in these conditions [1][2] - Traditional laboratory testing methods have limitations, including complex procedures and long detection cycles, which the new chemiluminescence method overcomes by simplifying operations and enhancing sensitivity and specificity [1] Group 2: Clinical Implications and Market Position - The introduction of the soluble CD146 detection kit is expected to transition the field of central nervous system immune inflammatory demyelinating diseases from "diagnosable" to "precise and early diagnosis," laying a crucial foundation for disease intervention and prognosis improvement [2] - The collaboration with Academician Yan Xiyun, a prominent figure in nanobiology and tumor immunology, highlights the innovative nature of this project and strengthens China's international position in the diagnostic field for these diseases [2]

Core Insights - Aihuilong (688575.SH) has received approval from the Guangdong Provincial Drug Administration for its self-developed soluble CD146 detection kit (chemiluminescence method), marking a significant breakthrough in the detection of central nervous system diseases [1] - Aihuilong is the first company globally to possess a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Clinical Significance - Research indicates that the concentration of soluble CD146 (sCD146) in cerebrospinal fluid is significantly elevated in patients with central nervous system autoimmune inflammatory demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica [2] - Traditional laboratory testing methods for these diseases have limitations, including complex procedures and long detection cycles, which Aihuilong's innovative chemiluminescence method aims to overcome by simplifying operations and enhancing sensitivity and specificity [2][3] - The sCD146 level in cerebrospinal fluid has shown a strong correlation with various inflammatory factors, making it a crucial auxiliary diagnostic marker for early and precise diagnosis of these diseases [2] Group 2: Technological Innovation - The soluble CD146 detection kit represents a groundbreaking technological achievement developed in collaboration with Professor Yan Xiyun, a renowned academician and expert in nanobiology [4] - This innovation not only transforms the diagnostic approach for central nervous system autoimmune inflammatory demyelinating diseases but also strengthens China's international leadership in this diagnostic field [4] - Aihuilong is conducting multi-center studies with Xuanwu Hospital to establish new diagnostic technologies and solutions based on sCD146, with plans to expand its application in various medical fields, including obstetrics, autoimmune diseases, cardiovascular diseases, and oncology [4]

关于自愿披露取得医疗器械注册证的公告 证券代码：688575 证券简称：亚辉龙 公告编号：2025-059 深圳市亚辉龙生物科技股份有限公司 sCD146 是中国科学院生物物理研究所阎锡蕴院士发现的创新型指标，亚辉龙与阎 院士团队携手，持续探索以该指标为靶点的诊疗方案。目前，亚辉龙分别与北京大学第 一医院、北京宣武医院、北京大学第三医院等国内顶尖医疗机构，围绕 sCD146 的潜在 应用领域开展深入课题研究。本次获批的诊断试剂产品，是亚辉龙与阎院士团队历时多 年攻关达成的产学研转化成果，也是 sCD146 这一创新标志物在全球范围内实现转化的 首个检测试剂。 截至目前，公司已先后取得 173 项化学发光试剂国内《医疗器械注册证》（共 250 个发光试剂国内注册证）。本次《医疗器械注册证》的取得，有利于进一步丰富公司的 全自动化学发光产品线，增加了亚辉龙的神经系统疾病领域检测套餐。 三、风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）于近日收 到了由广 ...

CD146 最早被发现于黑色素瘤、前列腺癌和乳腺癌细胞上，后研究发现CD146存在膜型和可溶性两种 形式，其中膜形式的 CD146 广泛分布于血管内皮细胞、平滑肌细胞、淋巴细胞等组织细胞上，起到血 管发生发展、细胞黏附迁移、免疫应答及细胞分化等作用。膜型 CD146 的胞外区经过金属蛋白酶切割 等生理过程，从细胞表面脱落进入组织液中，形成可溶性 CD146（soluble CD146，sCD146）。sCD146 与膜型CD146 相比，缺失胞内区域和跨膜区域，其余结构与膜型 CD146 相同。研究表明，在多发性硬 化症、视神经脊髓炎等中枢神经系统免疫性炎性脱髓鞘病人中，血脑屏障内皮细胞中的膜型CD146表达 升高，同时由于金属蛋白酶的表达增加等因素，脑脊液中sCD146 的浓度明显升高。在中枢神经系统免 疫性炎性脱髓鞘病人的脑脊液中，sCD146 的浓度与多种炎症因子（如TNFα、IFNγ、IL-2、IL-17A 等）的浓度呈正相关，且相较于其他与疾病进程相关的分子标志物，如金属蛋白酶（MMP2、 MMP9）、可溶性粘附因子（sICAM、sVCAM）、炎症因子（LI-1β、IL-17A、IL-10、IFN- ...

Core Insights - Company Aihuilong (688575.SH) has received a medical device registration certificate for its soluble CD146 detection kit, marking a significant milestone in its product development [1] Group 1: Product Development - The product, named soluble CD146 detection kit (chemiluminescence method), has been registered with the Guangdong Provincial Drug Administration under registration number 20252401494 [1] - This diagnostic product is the first test kit globally to utilize the innovative biomarker soluble CD146, which was discovered by Academician Yan Xiyun from the Institute of Biophysics, Chinese Academy of Sciences [3] Group 2: Research and Collaboration - Aihuilong is collaborating with top medical institutions, including Peking University First Hospital, Beijing Xuanwu Hospital, and Peking University Third Hospital, to explore the potential applications of soluble CD146 [3] - The approval of this diagnostic reagent is a result of years of research and development in partnership with Academician Yan's team, showcasing the successful transformation of academic research into practical medical solutions [3] Group 3: Market Position and Product Line - With this new registration, Aihuilong has now obtained a total of 173 domestic medical device registration certificates for chemiluminescent reagents, contributing to a total of 250 such registrations [3] - The new product enhances Aihuilong's portfolio in the field of neurological disease diagnostics, expanding its automated chemiluminescence product line [3]

Core Viewpoint - The enthusiasm for applying for green factory certification has significantly increased among enterprises, driven by policy support and market demand, with a total of 1,382 new national-level green factories expected in 2024, bringing the cumulative total to 6,430 [1][5]. Summary by Sections Application Requirements Update - The application process for green factory certification has been simplified, with the removal of third-party evaluation reports, allowing companies to self-report through an online platform [2][3]. - The new evaluation criteria have been streamlined, reducing the number of secondary indicators from 92 to 14, focusing on five primary indicators: energy decarbonization, resource efficiency, clean production, product greenness, and land intensiveness [2][3]. Increased Standards for Certification - The evaluation now emphasizes quantitative assessments, with 11 out of 14 secondary indicators being quantitative, requiring companies to meet industry benchmarks for energy consumption and carbon emissions [3]. - The weight of the "energy decarbonization" criterion is set at 30%, necessitating detailed calculations of energy consumption and carbon emissions [3]. Corporate Engagement in Green Factory Applications - The number of applications for green factory certification has surged due to local government incentives, with financial rewards ranging from 200,000 to 1,000,000 yuan for successful applicants [5]. - Companies are increasingly motivated to pursue green factory status to comply with stricter environmental regulations and to enhance their market competitiveness [5][6]. Technological Innovation and Digital Management - Enterprises are leveraging technological innovations and digital management to facilitate their green transformation, focusing on energy efficiency and carbon reduction [7][8]. - The integration of digital technologies, such as IoT sensors and data analytics, is becoming crucial for real-time monitoring and optimization of energy consumption [8][9]. Recommendations for Companies - Companies are advised to maintain comprehensive records of their energy consumption and emissions data to support their green factory applications [9]. - It is recommended that enterprises prepare for certification by implementing systematic management practices and aligning with industry standards for sustainability reporting [9].

Core Points - The Shanghai Composite Index is currently at 3996.35 points, above the annual line, with a decline of 0.16% and a total trading volume of 1,602.079 billion yuan [1] - A total of 32 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates include Mannesmann (5.00%), Yahui Long (4.97%), and Xuan Ya International (4.31%) [1] - Mannesmann's stock price increased by 7.00% with a turnover rate of 18.49% [1] - Yahui Long's stock price rose by 6.78% with a turnover rate of 3.82% [1] - Xuan Ya International's stock price increased by 6.82% with a turnover rate of 17.96% [1] Other Notable Stocks - ST Nuotai and Digital People also showed positive performance with increases of 3.64% and 3.22%, respectively [1] - The stocks with smaller deviation rates that just crossed the annual line include Jianhui Information, Sinopec, and Xianggang Technology [1] Trading Volume - The total trading volume of A-shares today reached 1,602.079 billion yuan, indicating active market participation [1]

Group 1 - The core point of the news is that Aihuilong's stock price increased by 5.21% to 16.15 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.77%, resulting in a total market capitalization of 9.212 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay methods [1] - The company's revenue composition includes self-produced reagents (non-COVID products) at 58.57%, self-produced consumables (non-COVID products) at 12.60%, self-produced instruments (non-COVID products) at 11.92%, and various agency sales [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund holds a significant position, having reduced its holdings by 1.7669 million shares in the third quarter, now owning 9.6516 million shares, which is 1.69% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) has a total scale of 26.404 billion CNY and has achieved a year-to-date return of 11.75% [2] - The fund manager, Hu Jie, has a tenure of 13 years and 31 days, with the fund's total asset scale reaching 100.204 billion CNY [3]

Core Viewpoint - Recently, the company received a medical device registration certificate issued by the National Medical Products Administration for its product, the Human Chorionic Gonadotropin and β Subunit Determination Kit (Chemiluminescence Method) [2] Company Summary - The product is designed for the determination of human chorionic gonadotropin and its β subunit, indicating its application in medical diagnostics [2] - The approval from the regulatory authority signifies a potential expansion in the company's product offerings and market reach [2] Industry Summary - The announcement reflects ongoing developments in the medical device sector, particularly in diagnostic tools [2] - Regulatory approvals are crucial for companies in the healthcare industry, as they can lead to increased market opportunities and revenue growth [2]